Sanofi Files New Pompe Hope Avalglucosidase Alfa In EU

Review Is Standard, Not Accelerated As Requested

The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.

Lyon France, 3 October 2017: White logo of the french multinational pharmaceutical company Sanofi on their glass office building in Lyon France
Sanofi Looks To Keep The Lead In Pompe Disease • Source: Shutterstock

Sanofi's strategy of defending its position in Pompe disease, a space where the French company's Myozyme/Lumizyme is the only approved therapy, has been kickstarted by the EU filing of avalglucosidase alfa.

The European Medicines Agency has accepted the French major's marketing authorization application for avalglucosidase alfa for long-term enzyme replacement therapy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip